1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Hemorrhagic Fever - Pipeline Review, H1 2014

Hemorrhagic Fever - Pipeline Review, H1 2014

  • June 2014
  • -
  • Global Markets Direct
  • -
  • 65 pages

Hemorrhagic Fever - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Hemorrhagic Fever - Pipeline Review, H1 2014’, provides an overview of the Hemorrhagic Fever’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hemorrhagic Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemorrhagic Fever and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hemorrhagic Fever
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hemorrhagic Fever and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hemorrhagic Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hemorrhagic Fever pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hemorrhagic Fever
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hemorrhagic Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hemorrhagic Fever - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hemorrhagic Fever Overview 7
Therapeutics Development 8
Pipeline Products for Hemorrhagic Fever - Overview 8
Pipeline Products for Hemorrhagic Fever - Comparative Analysis 9
Hemorrhagic Fever - Therapeutics under Development by Companies 10
Hemorrhagic Fever - Therapeutics under Investigation by Universities/Institutes 12
Hemorrhagic Fever - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Hemorrhagic Fever - Products under Development by Companies 16
Hemorrhagic Fever - Products under Investigation by Universities/Institutes 17
Hemorrhagic Fever - Companies Involved in Therapeutics Development 18
Peregrine Pharmaceuticals, Inc. 18
BioCryst Pharmaceuticals, Inc. 19
SIGA Technologies, Inc. 20
Evolva SA 21
Integrated BioTherapeutics, Inc. 22
Hawaii Biotech, Inc. 23
Navigen Pharmaceuticals, Inc. 24
Hemorrhagic Fever - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
Vaccine For Hemmorrhagic Fever With Renal Syndrome - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
DNA Vaccines - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
EV-075 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
bavituximab - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Panfilovirus VLP Vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
EMER-FAB Project - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Tick-Borne Flavivirus Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
BCX-4430 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
ST-161 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Slit2N - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Hemorrhagic Fever - Recent Pipeline Updates 50
Hemorrhagic Fever - Dormant Projects 59
Hemorrhagic Fever - Discontinued Products 60
Hemorrhagic Fever - Product Development Milestones 61
Featured News and Press Releases 61
Sep 09, 2013: Data Supporting Bavituximab's Immunotherapy Mechanism of Action Published in the Peer-Reviewed AACR Journal Cancer Immunology Research 61
Jun 10, 2013: NanoViricides Submits DengueCide Orphan Drug Designation Application To FDA For Dengue And Dengue Hemorrhagic Fever 62
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65

List of Tables

Number of Products under Development for Hemorrhagic Fever, H1 2014 8
Number of Products under Development for Hemorrhagic Fever - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Hemorrhagic Fever - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2014 18
Hemorrhagic Fever - Pipeline by BioCryst Pharmaceuticals, Inc., H1 2014 19
Hemorrhagic Fever - Pipeline by SIGA Technologies, Inc., H1 2014 20
Hemorrhagic Fever - Pipeline by Evolva SA, H1 2014 21
Hemorrhagic Fever - Pipeline by Integrated BioTherapeutics, Inc., H1 2014 22
Hemorrhagic Fever - Pipeline by Hawaii Biotech, Inc., H1 2014 23
Hemorrhagic Fever - Pipeline by Navigen Pharmaceuticals, Inc., H1 2014 24
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Stage and Target, H1 2014 27
Number of Products by Stage and Mechanism of Action, H1 2014 29
Number of Products by Stage and Route of Administration, H1 2014 31
Number of Products by Stage and Molecule Type, H1 2014 33
Hemorrhagic Fever Therapeutics - Recent Pipeline Updates, H1 2014 50
Hemorrhagic Fever - Dormant Projects, H1 2014 59
Hemorrhagic Fever - Discontinued Products, H1 2014 60

List of Figures

Number of Products under Development for Hemorrhagic Fever, H1 2014 8
Number of Products under Development for Hemorrhagic Fever - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Top 10 Target, H1 2014 26
Number of Products by Stage and Top 10 Target, H1 2014 27
Number of Products by Top 10 Mechanism of Action, H1 2014 28
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 29
Number of Products by Top 10 Route of Administration, H1 2014 30
Number of Products by Stage and Top 10 Route of Administration, H1 2014 31
Number of Products by Top 10 Molecule Type, H1 2014 32
Number of Products by Stage and Top 10 Molecule Type, H1 2014 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


Download Unlimited Documents from Trusted Public Sources

Infectious Disease Statistics in the US

  • December 2016
    32 pages
  • Infectious Dise...  

    Asthma  

  • United States  

View report >

Infectious Disease Statistics in Africa

  • December 2016
    3 pages
  • Infectious Dise...  

    Therapy  

    Pharmaceutical  

  • Africa  

    World  

View report >

Infectious Disease Statistics in Brazil

  • December 2016
    9 pages
  • Infectious Dise...  

    Hospital  

  • Brazil  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.